Heron Therapeutics Inc  

(Public, NASDAQ:HRTX)   Watch this stock  
Find more results for NASDAQ:APPA
-0.46 (-5.50%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.86 - 8.61
52 week 6.51 - 15.82
Open 8.27
Vol / Avg. 216,664.00/107,511.00
Mkt cap 230.52M
P/E     -
Div/yield     -
EPS -2.94
Shares 29.18M
Beta 0.30
Inst. own 90%
Dec 10, 2014
Heron Therapeutics Inc at Oppenheimer Healthcare Conference - Webcast
Nov 24, 2014
Heron Therapeutics Inc at Brean Capital's Life Sciences Summit Conference
Nov 6, 2014
Q3 2014 Heron Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -76.63% -83.82%
Return on average equity -86.09% -91.56%
Employees 47 -
CDP Score - -


United States - Map
+1-650-3662626 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Heron Therapeutics, Inc. is a biotechnology company. The Company is using its proprietary technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. Heron�s product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. The Company�s product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies.

Officers and directors

Kevin C. Tang Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Robert H. Rosen President, Director
Age: 58
Bio & Compensation  - Reuters
Barry D. Quart Pharm.D. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Mark S. Gelder M.D. Senior Vice President, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Esme C. Smith Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Stephen R. Davis Director
Age: 53
Bio & Compensation  - Reuters
Craig A. Johnson Independent Director
Age: 53
Bio & Compensation  - Reuters
Kimberly J. Manhard Independent Director
Age: 54
Bio & Compensation  - Reuters
John W. Poyhonen Independent Director
Age: 54
Bio & Compensation  - Reuters